Phase 2 Advanced Unresectable Clinical Trials
22 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 22 trials
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma
BeOne Medicines30 enrolled6 locationsNCT07554521
Recruiting
Phase 1Phase 2
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.528 enrolled1 locationNCT06555068
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2
Neoadjuvant Tebentafusp for Uveal Melanoma
Locally Advanced Unresectable Uveal Melanoma
Thomas Jefferson University19 enrolled2 locationsNCT06414590
Recruiting
Phase 2
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.150 enrolled1 locationNCT07646626
Recruiting
Phase 2
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute30 enrolled1 locationNCT06434064
Recruiting
Phase 2
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Advanced Unresectable Hepatocellular Carcinoma
Riboscience, LLC.220 enrolled4 locationsNCT07175441
Recruiting
Phase 2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+3 more
University of Washington60 enrolled2 locationsNCT06179303
Recruiting
Phase 2
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
Esophageal Squamous Cell CarcinomaLocally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University118 enrolled1 locationNCT07519486
Recruiting
Phase 2
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Ning Jiang, M.D./Ph.D.98 enrolled1 locationNCT07530094
Recruiting
Phase 1Phase 2
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
MetastaticAdvanced Unresectable
Beijing Biotech72 enrolled1 locationNCT07523529
Recruiting
Phase 1Phase 2
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Advanced Unresectable or Metastatic Breast Cancer of Adults
Shandong Suncadia Medicine Co., Ltd.180 enrolled2 locationsNCT07389733
Recruiting
Phase 2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Esophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
AbbVie180 enrolled49 locationsNCT06628310
Recruiting
Phase 1Phase 2
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.300 enrolled2 locationsNCT06679036
Recruiting
Phase 2
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Jiangsu Cancer Institute & Hospital22 enrolled1 locationNCT07435454
Recruiting
Phase 2
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien45 enrolled8 locationsNCT07039162
Recruiting
Phase 2
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric Adenocarcinoma+10 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT06251973
Recruiting
Phase 2
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Metastatic MelanomaAdvanced Unresectable Melanoma
Kevin Kim, MD10 enrolled1 locationNCT07237100
Recruiting
Phase 2
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Colo-rectal CancerMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Fudan University40 enrolled1 locationNCT07003022
Recruiting
Phase 1Phase 2
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.368 enrolled6 locationsNCT05636215